Mylan wins permanent injunction against GSK’s generic Paxil
Notice: Undefined variable: article_ad_placement3 in /usr/web/cs-washington.ogdennews.com/wp-content/themes/News_Core_2023_WashCluster/single.php on line 128
CANONSBURG – Mylan Inc. said Thursday that the U.S. District Court for New Jersey granted its motion for a permanent injunction against GlaxoSmithKline in relation to Paroxetine CR, the generic version of GSK’s Paxil CR.
According to a news release from Mylan, GSK is now precluded from supplying product to Apotex, which marketed the product as an authorized generic. Mylan had previously been awarded damages in the amount of $106,700,000 by the district court after a favorable jury verdict in March 2014.
In addition, the court awarded Mylan prejudgment interest and permitted it to take an accounting so that Mylan can determine the amount of additional damages it has suffered since Sept. 30, as a result of GSK’s ongoing breach. All of GSK’s post-trial motions were denied.
Southpointe-based Mylan is the only company to have successfully developed an FDA-approved generic version of the product, which is used to treat depression.